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(Sponsored by George Tellides, Section of Cardiothoracic Surgery,  
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ABSTRACT:  Lymphocyte Activation Gene-3 (LAG-3) is a soluble protein and transmembrane 
protein receptor expressed on lymphocytes such as immunosuppressive regulatory T cells.  Our 
goal was to evaluate the effect of LAG-3 on transplantation outcomes, specifically rejection and 
cellular memory response to donor antigen, by comparing graft survival and IFN-l secretion to 
donor antigen in C57BL/6 LAG-3-/- versus wild-type mouse recipients of DBA/2 grafts.  We 
found that LAG-3 deletion accelerates rejection time and enhances IFN-l secretion among heart 
or skin graft recipients.  FACS analysis of memory T cells demonstrated disproportionate 
increases in effector T cell subsets, consistent with a heightened rejection response.  Although the 
absence of LAG-3 enhanced rejection of heart and skin grafts, it did not abrogate tolerance of 
spontaneously accepted kidney allografts.  To further understand the mechanism of LAG-3 
signaling and the potential importance of dendritic cells, we cultured donor dendritic cells in a 
tolerogenic milieu with recipient T cells and found increased PD-1 and IL-10 expression among T 
cells.  Lastly, we performed soluble LAG-3 injections and adoptive transfers of LAG-3+/+ cells 
into knock-out graft recipients.  This demonstrated that the presence of LAG-3 on T cells is 
critical for mediation of rejection, while LAG-3 on dendritic cells downregulates donor-specific 
IFN-l secretion.  Our data suggest that in addition to LAG-3’s effects on proliferation and 
activation, LAG-3 may also affect differentiation of precursor CD4+ T cells.  Additionally, these 
data indicate the importance of dendritic cell-mediated control of the memory response in a LAG-
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Heart transplantation has become a mainstay treatment for patients with severe 
end-stage heart failure despite maximum medical therapy.  Since 1967, one-year survival 
rates have jumped from 30% to 85-90%, and current three-year survival approaches 75% 
(1, 2).  A significant proportion of late mortality after the first year is attributable to the 
usage of broadly immunosuppressive drugs that enable systemic infections and cancers 
such as post-transplant lymphoproliferative disease (PTLD) or non-Hodgkin lymphoma 
(2).  What is needed are new therapies that allow for the targeted induction, proliferation 
or activation of narrow cellular and non-cellular immune system elements that 
specifically enhance allograft protection while preserving systemic host defenses against 
infections and cancers.  One possible solution involves the therapeutic alteration or 
introduction of glycoprotein moieties to increase the temporally- and locationally-specific 
proliferation or activation of regulatory cells.  If donor allografts can be modified to 
express immunosuppressive glycoprotein moieties, it could downregulate local immune 
reactions while preserving systemic immune responses. 
A. LAG-3 Structure & Function 
 
 
Fig. 1: A History of LAG-3 
	 6 
Discovered in 1990, LAG-3 is primarily known as a Type I cell-surface 
membrane receptor and on human chromosome 12p13 is adjacent to CD4, a gene with 
which it possesses 20% sequence homology (3).  It is believed that LAG-3 and CD4 may 
have resulted from a gene duplication and likely share common regulatory elements (4).  
LAG-3 binds with greater avidity to the MHC-TCR complex, suggesting that it may 
block CD4 pathways and therefore full T cell activation (4, 5).  Little is known about the 
direct intracellular effects of LAG-3, though the original paper wherein the protein was 
described demonstrated that LAG-3 modifies extracellular calcium influx in a CD3/TCR-
dependent manner (6). 
LAG-3 has at least one other splicing variant, a soluble protein (5).  
Transcriptional control governs whether LAG-3 is trafficked to the cell-surface as a 
receptor or extruded into the serum.  Depicted below (Figs. 2, 3) is the structure of the 
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Fig. 2: LAG-3 Structure Fig. 3: LAG-3 Soluble vs. Membrane-Bound 
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Signaling through the cell-surface isoform occurs on effector T cells after binding 
MHC II, which negatively regulates T cell function as shown above (5).  T cells signal 
downstream via cytoplasmic KIEELE motifs, resulting in decreased cellular proliferation, 
cytokine inhibition, and reduced cytolysis, but the intermediary pathway steps have not 
yet been described (7).  Some DCs are also known to activate after binding LAG-3, either 
as a receptor or a soluble protein, using lipid raft microdomains.  It has also been 
theorized that in addition to interacting with MHC II molecules on DCs, LAG-3 can bind 
MHC II that has been acquired by regulatory T cells via trogocytosis (5).  LAG-3-MHC 
II interactions may be analogous in some ways to CD40L-CD40 interactions.  Both 
CD40L and CD40 are necessary for IL-12 and IFN-g production in antigen-presenting 
cells in vitro and upregulate LAG-3.  Similarly, soluble LAG-3 can directly induce DCs 
to produce Th1 cytokines and chemokines, such as CCL22 and CCL17, which helps 
direct migration of maturing DCs to lymph nodes (3).  LAG-3 may also modulate 
differentiation of DCs from monocyte precursors (8). 
 
B. Tr1 Regulatory Cells & Immunosuppression 
While FOXP3+  regulatory T cells (Tregs) are the quintessential regulatory cells, 
other immunosuppressive cell types exist, such as FOXP3- Tr1 cells generated from 
CD4+ memory T cells (9).  LAG-3 has gained attention in the field of transplant 
immunology in part due to its presence on Tr1 cells, which may be beneficial in 
dampening the post-transplant immune response.  Tr1 cells play an important role in 
reducing autoimmune colitis and encephalomyelitis in mice and in controlling reactive 
arthritis and multiple sclerosis in humans (10-13).  Moreover, Tr1 cells may fill 
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immunological niches not served by Tregs.  In contrast to FOXP3+ Tregs, Tr1 cells 
suppress NLRP3 inflammasome activation via an IL-10-dependent mechanism (14).  It 
has also been proposed that while natural Tregs are critical early in an immune response 
for controlling the magnitude of inflammation, Tr1 cells become important later for 
maintaining tolerance (11).  The strong potential for Tr1 cells to serve as an 
immunomodulatory clinical treatment relates to their higher propensity for inducing local 
tolerance against non-self antigens in the periphery, unlike thymus-derived or some 
peripherally-derived regulatory T cells (15).  This characteristic makes Tr1 cells natural 
candidates for controlling inflammation against allogeneic transplants.  In fact, recent 
studies demonstrate that antigen-specific Tr1 cells are critical for: 1) restoring insulin 
production in patients with Type 1 diabetes, 2) facilitating pancreatic islet transplant 
tolerance in PTPN22 deficiency, 3) promoting tolerance to mismatched HLA stem-cell 
transplants in SCID patients, and 4) preventing mouse skin allograft rejection (12, 15).   
Tr1 cells in the periphery have long been characterized as CD4+FOXP3+CD226+ 
and by a cytokine production profile of IL-10+, IL-4-, TGF-b+, IL-5+, IL-2low/-, IFN-g+/- (9, 
15-17).  These markers, however, were too broad to efficiently track Tr1 lineage and 
movement.  In a 2013 Nature paper, Gagliani et al. used differential gene expression in 
human blood and immunohistochemical profiles of murine gut isolates to streamline the 
identification of Tr1 cells as IL-10-secretors that co-express CD49b and LAG-3 (9).  
LAG-3 can be expressed as either a transmembrane protein that downregulates TCR-
mediated signal transduction in human and mouse lymphocytes or as a soluble molecule 
that activates dendritic cells (DCs) and enhances antigen-specific T cell responses (15).  
Interestingly, exogenously-induced expression on Tregs of LAG-3, like Tr1 induction, 
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requires IL-27 (18).  The role of LAG-3 on Tr1 cells has not yet been specified, however.  
Moreover, its intracellular pathways have not fully been elucidated, apart from a 
description of its cytoplasmic tail receptors (19). 
Tr1s generated in vitro using IL-27 and TGF-b co-expressed CD49b and LAG-3 
for up to 12 days in culture and up to 13 days after in vivo transfer (9).  Markers of Tr1 
activation include CD28, CD69, CTLA4, CD25, IL-2Rbg, CD40L, and HLA-DR (11, 
15).  Tr1 cells can express FOXP3 but only transiently (15).  Interestingly, 
CD4+CD49b+LAG-3+ differentially express certain receptors (low epidermal growth-
factor receptor 2 (Egr2) but high Aryl hydrocarbon receptor (Ahr)), suggesting a 
different process of IL-10 production from that principally used by Tregs (9).  Tr1 cells 
express AhR and require c-Maf, IL-21, and ICOS for IL-27-dependent activation (12, 15, 
20, 21).  AhR binds c-Maf in Tr1 cells and enhances transcription of IL-10 and IL-21, 
secretion of which is important in Tr1 induction as it maintains C-Maf expression 
through a feed-forward transcription loop (12).  IL-6 has also been implicated in driving 
expression of c-Maf and AhR, as well as IRF-4, another critical transcription factor for 
IL-10 secretion and Tr1 differentiation, via a STAT3 promoter pathway (15, 22).  
 
C. Galectin Signaling & Tr1 Cells 
Galectins are a family of broadly-expressed mammalian carbohydrate-binding 
proteins defined by a common b-sandwich structure; they function in multiple 
compartments to regulate immune responses by binding glycan ligands, particularly b-
galactosides (23, 24).  It is plausible that variations in glycosylation patterns affect the 
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binding affinity of galectins, which control downstream transcription factors that alter the 
likelihood of transplant acceptance.  
Galectin-3 (Gal-3) modulates TCR activation threshold on naïve T cells and 
galectin-1 (Gal-1) influences TCR signaling in developing thymocytes by altering 
negative selection via the ERK pathway (25).   Of all known galectins, Gal-1 also has the 
strongest evidence for activating and proliferating Tr1 cells by binding CD45 so that 
TCR signaling is muted. This is may be due to the prevention of Lck phosphorylation, 
allowing Tr1 induction via an intracellular mechanism that involves IL-27.  However 
further clarification is required (26).   
Interestingly, LAG-3, the transmembrane receptor that along with CD49b defines 
Tr1 cells, has been shown to bind galectin-3 in vivo to induce immunosuppression by 
blocking IFN-g production and CD8+ cytotoxicity (27, 28).  If LAG-3 serves a similar 
function on Tr1s as it does on T effectors, then it is plausible that LAG-3 on Tr1 cells 
may be used to selectively trigger Tr1-mediated graft protection.  If true, this would 
suggest that existing rates of cardiac allograft tolerance can be further improved using 
galectins and possibly custom-designed therapeutics that mimic glycoproteins structures 
necessary for activating LAG-3 receptors.  
 
D. Accepting and Rejecting Mouse Allograft Models 
Because of its relatively short lifespan, the variety of MHC combinations that can be 
tested across strains, and the wide availability of commercially-available genetic 
knockouts, the mouse is a suitable model organism to measure the effects of donor-host 
incompatibility.  It has been shown that the rejection pattern and timing can differ 
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markedly both across strain combinations and organ types (29).  The particular MHC 
combination used in this study, H-2b to H-2d, has been reported to exhibit an average 
survival of 9.6±0.4 days for cardiac allografts for C57BL/6 to BALB/c (29).  In general, 
major allele differences across various strain combinations cause rejection in 7-10 days 
(30-32).  For the purposes of this study, the heart and skin models are referred to as 
“rejection models” because without host immunosuppression they ultimately result in 
graft failure.  In contrast, in some strain combinations of donors and recipients, kidney 
allografts do not undergo failure, even after an extended time period.  For instance, 
DBA/2 (H-2d) kidneys transplanted into C57BL/6 (H-2b) recipients have been reported to 
maintain their function beyond 60 days, for unknown reasons (33).  In this study, kidney 
allografts between these mouse strains are referred to as an “accepting model” because 
they do not typically reject in the long-term even without host immunosuppression. 
 
Statement of Purpose 
 Though LAG-3 has been investigated in cancer and infectious diseases research, 
its role or lack thereof in transplantation needs to be clarified.  Specifically, our main 
objective is to determine whether LAG-3 simply identifies Tr1 cells or whether it plays a 
functional role in mediating rejection or graft-protection.  If LAG-3 does modulate 
rejection, it is important to investigate its effects in both the short-term (acute rejection) 
versus the long-term (immunologic memory).  Additionally, characterization of LAG-3’s 
disparate effects, if any, on a rejecting model of heart or skin allografts versus a 
spontaneously accepting model of kidney allograft is important.  Another objective is to 
assess whether Gal-3, insofar as it has been reported to be a ligand for LAG-3, modulates 
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the function of LAG-3, particularly with respect to the expression of receptors theorized 
to be important for graft-protection, such as Foxp3 and IL-10.  Finally, if LAG-3 deletion 
demonstrates a measurable transplant effect, it will be important to discriminate between 
effects mediated via its soluble form or its membrane-bound form (including its 
corresponding cell type).  We therefore propose the following research aims, hypotheses, 
and methods: 
 
Research Aim  Hypothesis Method(s) 
1. To assess whether LAG-
3 levels influence acute 
allograft rejection  
LAG-3 mediates 
allograft rejection 
A. Murine heart and skin 
transplantations  
B. Histologic examination 
 
2. To assess whether LAG-
3 is important for 
immunologic T cell 
memory 
LAG-3 mediates T 
cell memory 
development 
C. Murine heart and skin 
transplantations 
D. Splenocyte isolation and 
ELISPOT for IFN-g secretion 
to donor antigen 
3. To assess whether the 
function of LAG-3 
differs between 







E. Murine heart and skin 
transplantations 
F. Murine kidney transplantations 
4. To assess whether 
activation of LAG-3, via 
Gal-3, affects the 
Gal-3 enhances 
the effects of 
LAG-3 on graft-
A. Co-culture of T cells and DCs 
B. Assessment of IL-10 secretion 
G. FACS assessment of Foxp3, 
PD-1, IL-10 expression  
Table 1: Research Aims, Hypotheses, & Methods 
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expression of Foxp3, 
PD-1, and IL-10 
protective receptor 
expression 
5. To assess which form of 
LAG-3 (receptor or 




receptor, due to its 
downstream 
effects on T cell 
effectors, is more 




A. Adoptive transfer with LAG-3-
competent T-cells or DCs 
B. Pre-treatment with soluble 
LAG-3 
C. Murine heart and skin 
transplantations 
 
Methods   
Bolded initials denote which author performed which methods. 
 
Skin, heart, and kidney transplants 
 Transplants were performed between allogeneic DBA/2 (H-2d) donors and 
C57BL/6 (H-2b) recipients as well as DBA/2 donors and LAG-3-/- recipients on a 
C57BL/6 background.  In some cases, experimental controls consisted of identical 
surgeries performed between syngeneic donor and recipient (C57BL/6 to C57BL/6).  All 
mice were purchased from Jackson Labs.  Shaved skin was harvested from the right 
dorsum of donors between the forearm and the hindleg and transplanted within a few 
hours to the same location on the recipient (JME).   Donor hearts were transplanted 
heterotopically in the abdomen by dissecting out the mesentery to the right of the midline 
and anastomosing the donor aorta and pulmonary vein to the recipient aorta and inferior 
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vena cava, respectively (CY).   Donor kidneys were transplanted into the peritoneal 
cavity near the midline after complete resection of both recipient kidneys, followed by 
attachment of the donor ureter to the recipient bladder (CY).  Surgical tools were 
autoclaved prior to use, and donors and recipients were operated on using different sets of 
sterile tools (JME).   
 
Graft survival assessment 
 Survival of skin grafts was assessed via visual inspection for evidence of 
dessication and necrosis between 8-15 days post-transplant (JME).  Heart grafts were 
assessed via abdominal palpation (JME).  Grafts were harvested (JME) from different 
sets of mice at weeks 1 and 2 stained with H&E for pathologic analysis (RW, IR).  
Kidney grafts were evaluated by measuring spectrophotometrically the BUN levels of 
sera collected from cheek veins (JME).  Grafts were categorized as rejected if BUN 
exceeded 100 mg/dL (JME).   
 
Adoptive transfer & cytokine pre-treatment 
 In some experiments, T cells were isolated from spleens and bone marrow 
collected using mechanical separation and chemical isolation (Stem Cell Tech) from WT 
C57BL/6 animals (JME, DN).  DCs were isolated from both spleens and bone marrow 
using the same kits (JME).  Cells were injected on the same day into tail veins of either 
WT or LAG-3-/- animals, one week prior to skin engraftment (JME).  Other animals 
received soluble LAG-3 (sLAG-3, R&D Systems) injections via peritoneal injection one 




ELISPOT assay  
 ELISPOT was performed using PVDF 96-well plates pre-washed with 70% 
ethanol, washed three times with PBS, then coated with IFN-g primary antibody diluted 
1:100 in PBS for at least 4 hours at room temperature (JME, DN).  Isolated cells were 
seeded at 100,000 cells/well (JME), along with irradiated 250,000-cell aliquots from 
DBA/2, C57BL/6 or C3H mouse spleens (DN).  Cells were cultured overnight at 37C in a 
CO2 incubator (JME).  After 24 hours, plates were washed three times with PBS 0.1% 
Tween 20 (JME).  Each well received 100 uL of biotinylated IFN-g secondary antibody 
diluted 1:100 in PBS for 2 hours at room temperature (JME).  After washing, wells were 
incubated with streptavidin-horseradish peroxidase (diluted 1:5000) for 1 hour at 37C 
(JME).  Plates were washed with hydrogen peroxide substrate for 7-10 minutes at room 
temperature and dried 24-48 hours (JME).  Spots were counted using an automated 
protocol in ImmunoSpot Suite 5.0 (JME, AA).  
 
Plasmacytoid dendritic and T cell co-cultures 
 Splenic and bone marrow lymphocytes were isolated from DBA/2, C57BL/6, or 
LAG-3-/- C57BL/6 mice using gentle mechanical techniques followed by red cell lysis 
buffer (JME, DN).  Cells were resuspended in RPMI and processed using kits for pan-T 
or helper T cell isolation or DC purification (Stem Cell Tech) (JME).  Cell cultures were 
seeded in triplicates on 96-well plates at 50,000 cells/well for DCs and 150,000 
cells/well, first with T cells and irradiated DBA/2 splenocytes (for antigen presentation) 
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for 24-72 hours in complete growth medium (RPMI, FCS, streptomycin, penicillin, 
sodium pyruvate, and non-essential amino acids) at 37 C with 5% CO2 (JME).  Some 
wells were later combined with DCs after 72 hours, concurrently with the addition of 
combinations of various cytokines (Stem Cell Tech, R&D Systems) for an additional 120 
hours in these concentrations:  IL-15 (100 ng/mL), IL-27 (200 ng/mL), TGF-𝛽 (5 
ng/mL), Galectin-1 (100 ng/mL), Galectin-3 (200 ng/mL) (JME).  Cell media was 
changed every 24 hours for the first 72 hours, and then every 48 hours for the final 120 
hours (JME).  Cell isolates were analyzed for IL-10 secretion after 5 hours stimulation 
using PMA, Ionomycin, and Brefelden A (JME).     
 
Flow Cytometric Staining & Analysis 
 Cellular staining was conducted with dyes stored at 4C with minimal light 
exposure.  Prior to extracellular staining, mouse cells undergoing intracellular staining as 
well were pre-incubated with 1 ug of anti-mouse CD16/CD32 diluted in 100 uL of FACS 
buffer (PBS, 0.5% BSA, 0.1% sodium azide, DI water) for 15 minutes at 4C (JME).   
Cell isolates from organ separation and culture wells were transferred in aliquots of at 
least 50,000 cells in 1 mL of FACS buffer into 5 mL tubes and were washed at least 
twice using serial centrifugation at 1300 RPM for 8 minutes (JME, DN).  Extracellular 
stains were diluted in aliquots of 1:100 in FACS buffer, and mixed with cells for 30 
minutes at 4C with minimal light exposure.  Isolates undergoing intracellular (nuclear) 
staining were then washed in 500 uL of fixation/permeabilization solution (eBioscience), 
then incubated for an additional 60 minutes at room temperature, with minimal light 
exposure (JME).  Samples were washed twice in 1 mL of permeabilization buffer 
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(eBioscience) with centrifugation at 1300 RPM for 8 minutes at 4 C in between washes 
(JME).   After resuspension in buffer, cells were stained for 30 minutes at room 
temperature with minimal light exposure using 1:100 dye aliquots (JME).  Cells were 
rewashed twice in permeabilization buffer, followed by resuspension in FACS buffer 
prior to analysis on a 3-laser 8-color BD FACSVerse Analyzer (JME).  Samples were 
stored as necessary prior to analysis for up to 48 hours in 10% paraformaldehyde (JME).  
Sample gating was conducted in FlowJo v8 (JME, AA).   
 
Statistical Analysis 
 Kaplan-Meier analyses and Mann-Whitney U Tests were conducted in GraphPad 
Prism v7.0 (JME). 
 
Results 
Conclusion I: LAG-3 potentiates allograft survival and inhibits T cell memory 
generation in transplant rejection models 
 Transplant outcomes were compared between DBA/2 donor organs placed either 
with C57BL/6 or LAG-3-/- C57BL/6 recipients (Figs. 4, 5).  Heart grafts survived for an 
average of 7 days in LAG-3-/- recipients (n=4) versus an average of 9 days in wild-type 
C57BL/6 (WT) recipients (n=3), a difference that was statistically significant via log-rank 
testing (P=0.010).  Skin grafts survived for an average of 10 days on LAG-3-/- recipients 
(n=4) while skin on WT animals (n=4) survived for 13 days on average, a difference that 











Pathology assessments of heart and skin grafts revealed earlier necrosis in both 
graft sets (Fig. 6).   Although heart grafts placed in LAG-3-/- animals stopped beating a 
few days earlier on average, they showed pathologic evidence of ischemia with preserved 
tissue architecture in contrast to diffuse disruptive necrosis shown among grafts placed in 
WT recipients (Fig. 6).  Skin transplants displayed less epithelialization overall as well as 
faster necrosis and desiccation for up to two weeks after transplant.  
 
 















B/6 LAG-3 KO (n=3)
Log-rank (Mantel-Cox)
P=0.0100**
















B/6 LAG-3 KO (n=4)
Log-rank (Mantel-Cox)
P=0.0091**
Fig. 4: Heart Life Span Fig. 5: kin Life Span 
Fig. 6: Heart & Skin Allograft Inspection 
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 ELISPOT assays were performed for quantifying IFN-g secretion response toward 
DBA/2 donor antigen, relative to the response to third-party C3H antigen against which 
recipients had not been sensitized (Fig. 7).  T cells from LAG-3-/- heart recipient spleens 
(n=3) doubled their response, relative to WT T cells (n=3), toward DBA/2 and C3H in 
the first two weeks after transplant.  The relative LAG-3-/-  spot increase compared with 
WT cells reached almost ten-fold by the fifth week, for both DBA/2 and C3H antigens.  
By the fifth week, spot counts among LAG-3-/- animals at least doubled from the second 
week post-transplant.  Across all weeks, the difference between WT and LAG-3-/- 








 The response to skin grafts followed a different pattern, though the increase in 
antigenic response to DBA/2 was also markedly increased among LAG-3-/- (n=4) relative 
to WT (n=4) (Fig. 8).  To provide further time for vascularization, assessments were 
made at weeks 3-5 post-transplant.  As with hearts, response to DBA/2 grafts among 
LAG-3-/- animals rose consistently through the fifth week.  However, this pattern was not 
observed for C3H antigen (Fig. 8).  Across all time points, the LAG-3-/- cytokine response 



























































C3H Response, Heart Allograft
B/6 WT (n=3)

























DBA/2 Response, Heart Allograft
B/6 WT (n=3)
B/6 LAG-3 KO (n=3)
Fig. 7: IFN-g Secretion from Splenic T Cells After Heart Transplant 
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Conclusion II: LAG-3 deletion alters memory cell distributions and promotes 
differentiation of CD44hiCD62lo CD4+ T cells post-transplant 
 LAG-3-/- skin graft recipients demonstrated altered CD4+ and CD8+ 
compartments relative to WT recipients (Fig. 9).   While at five weeks post-transplant the 
proportion of CD44hiCD62lo effector memory cells showed relative stability in the WT 
animal, this proportion doubled in the LAG-3-/- animal.  The relative proportions of the 




























C3H Response, Skin Allograft
B/6 WT (n=4)

























DBA/2 Response, Skin Allograft
B/6 WT (n=4)





























Total DBA/2 Response, Skin Allografts
P=0.0055**
Fig. 8: IFN-g Secretion from Splenic T Cells After Skin Transplant 




 The differences in memory compartments can be appreciated by examining the 
trends in CD4+ and CD8+ sub-types across weeks 3-5 for skin graft recipients (Fig. 10).  
The percent expression of CD44hiCD62lo memory cells reaches about 30 percent only 
for LAG-3-/- CD4+ cells (Fig. 10).  Notably, no other memory subtype increased to this 






            
 
CD4+CD8- B/6 WT (n=4)
CD4+CD8- B/6 LAG-3 KO (n=4)
CD4-CD8+ B/6 WT (n=4)
CD4-CD8+ B/6 LAG-3 KO (n=4)
Total T Cells B/6 WT (n=4)























CD4+CD8- B/6 WT (n=4)
CD4+CD8- B/6 LAG-3 KO (n=4)
CD4-CD8+ B/6 WT (n=4)
CD4-CD8+ B/6 LAG-3 KO (n=4)
Total T Cells B/6 WT (n=4)























CD4+CD8- B/6 WT (n=4)
CD4+CD8- B/6 LAG-3 KO (n=4)
CD4-CD8+ B/6 WT (n=4)
CD4-CD8+ B/6 LAG-3 KO (n=4)
Total T Cells B/6 WT (n=4)
























CD4+CD8- B/6 WT (n=4)
CD4+CD8- B/6 LAG-3 KO (n=4)
CD4-CD8+ B/6 WT (n=4)
CD4-CD8+ B/6 LAG-3 KO (n=4)
Total T Cells B/6 WT (n=4)
Total T Cells B/6 LAG-3 KO (n=4)
Fig. 10: Memory Cell Compartments, Naïve vs. Skin Transplant 
	 22 
Conclusion III:  LAG-3 deletion causes fibrosis but does not inhibit tolerance 
induction of spontaneously accepted renal allografts 
 Next, we investigated the effect of LAG-3 deletion in an accepting model, given 
that the results from heart and skin graft rejection models were consistent with faster 
rejection in LAG-3-/- recipients relative to WT recipients (Fig. 11).  In certain cases, 
kidney transplants are spontaneously accepted despite MHC class differences between 
sub-species, notably DBA/2 donor and C57BL/6 recipient.  DBA/2 kidney transplants 
into LAG-3-/- C57BL/6 mice (n=2), compared against WT mice (n=2), did not show an 
appreciable increase in BUN levels, by which rejection was defined as exceeding 100 
mg/dL (Fig. 11).  Nevertheless, histologic examination of graft tissue revealed greater 
fibrosis interspersed throughout and surrounding smaller T cell-rich perivascular regions.  
The data also suggest that Tr1 cells may not play a role in the induction of tolerance, as 
seen by the allograft kidneys surviving up to 46 days.  Whether Tr1 cells are needed for 
maintenance of the allograft will require further analysis and monitoring the recipients for 




Fig. 11: Kidney Fibrosis & BUN, Naïve vs. Kidney Transplant 
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Conclusion IV: LAG-3 deletion in a tolerogenic in vitro milieu upregulates PD-1, 
FOXP3, and IL-10 on regulatory T cells 
 To further investigate the results found in the kidney transplants, an in vitro model 
of the tolerogenic kidney environment was developed using donor plasmacytoid dendritic 
cells and recipient CD4 T cells.  Experimental cultures varied by treatment with Gal-3 
and either WT or LAG-3-/- to investigate the role of LAG-3 in tolerogenesis as well as the 
interplay LAG-3 and its reported ligand, Gal-3 (Fig. 12).  Deletion of LAG-3 on CD4+ 
cells promoted expression of both PD-1 and FOXP3, inhibitory markers associated with 
regulatory T cells.  Notably, Gal-3 treatment enhanced PD-1 expression only on LAG-3-/- 






Fig. 12: Gal-3 & LAG-3 Effects on CD4 Cell Expression of Foxp3, PD-1, IL-10 
	 24 
 
Conclusion V:  LAG-3 deletion on T cells are specifically responsible for enhanced 
graft rejection 
 Inspection of skin grafts on days 7 and 10 after transplant showed faster eschar 
development in LAG-3-/- versus WT recipients from days 7-10, despite similar levels of 
epithelialization and granulation tissue on day 7 (Fig. 13).  LAG-3-/- pre-treated with 
either dendritic cells or soluble LAG-3 one week prior to transplant also showed greater 
eschar formation compared with WT animals.  LAG-3-/- animals that received T cells, 
however, showed delayed eschar formation and persistence of granulation tissue up to 























Fig. 13: Skin Transplant Survival 
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Conclusion VI:  Dendritic cells, not T cells, are responsible for heightened memory 
response as measured by IFN-g secretion 
 Measurement of skin allograft responses again demonstrated higher DBA/2 and 
C3H cytokine secretion against DBA/2 and C3H antigens in LAG-3-/- relative to WT 
recipients (Figs. 14, 15).  LAG-3-/-  animals that did not receive pre-treatment, as well as 
those injected with T cells or soluble LAG-3, showed marked increases in IFN-g 
responses, consistent with the results demonstrated in heart graft recipients (see 
Conclusion I).  In contrast, LAG-3-/- animals that received dendritic cell pre-treatment one 
week prior to transplant did not show IFN-g increases and instead demonstrated levels 
similar to those of WT animals (Figs. 14, 15).   
 
              
 
Discussion 
LAG-3 is a soluble and transmembrane protein whose significance in solid organ 














































































Fig. 14: DBA/2 Response, Skin Allograft Fig. 15: C3H Response, Skin Allograft 
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subset of inducible peripheral regulatory T cells, an important aim of this study is to 
determine whether LAG-3 does not functionally mediate the rejection process and 
therefore simply identifies specific classes of regulatory cells, or whether LAG-3 directly 
mediates allograft rejection.  Because rejection can take multiple forms, most applicably 
either acute or chronic rejection, subsequently parsing out the time-dependent effect of 
LAG-3 deletion becomes a necessary goal.  This we achieved by examining LAG-3 
deletion on short-term graft survival as well as long-term immunological memory, as 
measured by IFN-l secretion in response to donor antigen.   
An important corollary is that to the extent there is a measurable effect of LAG-3 
on transplant outcomes, these effects likely depend on a specific isoform, either soluble 
or membrane-bound, and/or cell type.  This we investigated by re-introducing LAG-3 
either as a soluble protein or as a membrane-bound protein attached to either T cells or 
dendritic cells and trending transplant and memory outcomes.  In the context of 
investigating the effects of LAG-3, it became clear that LAG-3’s effects may differ based 
on whether the mouse transplant model of choice was a rejecting model (heart or skin) or 
an accepting model (kidney).  Due to an ambiguous effect of LAG-3 deletion in the 
accepting model, we created a T cell-dendritic cell co-culture environment mimicking 
that in the accepting model and noted the effect of LAG-3 deletion on immunological 
surface receptors. 
Given the aims outlined above, this study generated six conclusions (see Results) 
which have implications for our understanding of how LAG-3 functions immunologically 
in a transplantation context.  Additionally, the findings of the study delineate a clearer 
role for LAG-3 and its molecular functions with respect to important inhibitory markers, 
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particularly PD-1, FOXP3, and IL-10, as well as dendritic cells.  These conclusions and 
their implications will be discussed in turn. 
  
 Effects of LAG-3 on allograft survival and T cell memory generation in rejection models 
Our first results demonstrate that LAG-3 deletion accelerates rejection of cardiac 
and skin allografts by a few days in either case.  H&E staining of rejected cardiac 
allografts shows greater intercellular lymphocytic infiltration and distortion of graft 
parenchyma.  Grafts in LAG-3-/- recipients, on the other hand, show relatively preserved 
architecture but appear to develop greater vascular occlusion, suggesting that these grafts 
reject faster, possibly due to an ischemic T cell-mediated process.  Published evidence 
suggests that memory T cells directly mediate cardiac allograft vasculopathy in RAG-1-/- 
B/6 (H-2b) recipients of Balb/c (H-2d) cardiac allografts in an OX40/OX40L-dependent 
manner (34).  OX40L blockade in this study was associated with impairment of T-cell-
mediated vascular injury, a finding reflected in human patients with CAV.  Activated 
memory T cells present in human coronary arteries generate a significant proportion of 
infiltrating mononuclear cells contributing to vascular inflammation (35).  Furthermore, 
the causality may be bidirectional: while inflammation can lead to ischemia so can 
ischemia lead to inflammation.   In a separate study of allogeneic cardiac transplants 
among rats, the degree of vessel injury in ischemic injured allografts at 90 days post-
transplant was significantly greater than that in non-ischemic injured allografts (36).  It is 
possible therefore that ischemia can lead to greater degrees of inflammation and vice-
versa, generating a positive feedback mechanism leading ultimately to chronic rejection.  
Our findings corroborate the theory of T-cell-mediated vascular injury but with the 
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important distinction that these findings occurred in the knockout animals on a faster 
timescale, suggesting that LAG-3 inhibits the ischemic and inflammatory effects of T 
cells to a graft.  This is consistent with broadly accepted notions of LAG-3, namely that it 
retards T cell activation, proliferation, and inflammatory cytokine generation (5, 19, 37-
40).    
Consistent with the findings in heart, the model of skin engraftment showed that 
LAG-3-/- animals accelerated rejection as evidenced by greater epithelial disruption by 
day 9 post-transplant and older scar formation by day 13.  This additional evidence from 
a separate type of rejection model supports the theory that the absence of LAG-3 plays a 
measurable role in accelerating graft rejection.  Both the heart and skin models also 
generated significantly higher levels of IFN-𝛾 by T cells isolated from spleen in response 
to donor antigen (1.5-2.5x higher) at least three weeks out from surgery.  While the 
cytokine production of LAG-3-/- T cells in response to third-party C3H stimulators also 
exceeded that of wild-type T cells, suggesting a baseline level of LAG-3-dependent 
inhibition of T cell activity, the cytokine effect was proportionally higher for heart 
allografts at week 5.  Thus, the blanket effect on all cellular responses due to LAG-3 
deletion, consistent with the literature as described above, is shown by the effect on third-
party.  However, one novel finding of this study is the increased effect in LAG-3 
knockout animals, which cannot be accounted for by increased activity alone, but rather a 
combination of either increased differentiation or increased cellular generation.  
The second conclusion suggests that LAG-3 affects production of memory T cell 
differentiation.  In the inflammatory milieus after skin and heart transplants, LAG-3 
deletion increases splenic memory T cells as measured by IFN-𝛾 ELISPOT secretion.  
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FACS analysis of naïve WT and LAG-3-/- animals compared with skin transplant 
recipients 5 weeks later shows that transplantation increases the differentiation of 
CD44hiCD62Llo CD4+ memory T cells, a type of effector memory cells.  Memory T 
cells originate from naive thymic CD25- T cells that can develop into CD25+ effector T 
cells (41).  In mice some of these T cells can become memory T cells, as distinguished by 
CD62L (L-selectin) and CD44 (H-CAM) (42).  Memory cells express low levels of L-
selectin in contrast to naïve cells; however, naïve cells express low levels of HCAM 
relative to memory cells.   Effector memory cells have been broadly associated with 
inflammation secondary to numerous causes, such as infection, allergens, and chemical 
irritants (42, 43).  Recently, the field has also highlighted the importance of memory T 
cells in mediating graft rejection and their role as a significant barrier to tolerance 
induction in clinical transplantation, since these alloreactive cells reside in and recirculate 
among peripheral non-lymphoid tissues associated with the graft (15, 44, 45).  Our 
findings in this study suggest that LAG-3 dampens the effect of memory T cell 
generation, which occurs at an exceedingly higher rate when LAG-3 is deleted.  This 
novel finding is particularly important for transplantation because co-stimulation 
blockade, a staple of immunological therapies, does not adequately control the responses 
of memory T cells (45).   These results are mutually substantiated by those mentioned 
earlier, specifically that memory cells have been associated with chronic allograft 
vasculopathy.   It is possible that the same mechanism that upregulates acute cellular 




Effects of LAG-3 on allograft survival and cell differentiation in an accepting model 
Spontaneously accepted renal allografts show smaller Treg-rich regions with 
higher fibrosis, but BUN levels do not reach a rejection level (>100 mg/dL) by 6 weeks. 
Beyond this time period, long-term graft follow-up and analysis may reveal a different 
pathology.  The difference in these observed allograft acceptance results could in part be 
dependent on the varying roles of LAG-3 on different T cell populations in either a 
rejection or tolerogenic milieu.   It has been established that T cell fates are highly 
dependent on the cytokine microenvironment to which they are exposed at various stages, 
and that ultimately graft survival in a host depends on whether its T cells largely take on 
a pro-inflammatory or pro-tolerant phenotype (46).  While the BUN findings did not 
suggest a rejection process, cellular histology did demonstrate increased parenchymal 
fibrosis indicative of a chronic inflammatory process.  One explanation for this finding 
could be that while LAG-3 does indeed accelerate inflammation, it has a countervailing 
and separate effect in a microenvironment of cytokines that are tolerogenic, or at least 
graft-protective.   
In spontaneously accepted renal allografts, in which regulatory cytokines or 
proteins such as IL-27, TGF-b, and Gal-1 are upregulated or conserved (unpublished 
observations based on RNA transcript analysis), stimulation of CD4+ naïve cells with 
tolerogenic allogeneic DCs depends in part on LAG-3.  In in vitro assays that replicate 
this tolerogenic milieu, LAG-3 deletion increases expression of PD-1 and IL-10 on 
regulatory T cells analyzed by FACS staining.  At first glance, this finding contrasts with 
past research that shows that the development of naïve CD4+ cells can be shunted toward 
a regulatory phenotype, most notably Tr1 cells, in LAG-3 dependent processes in the gut 
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and in tumors (18, 47, 48).   However, it may be that with germline deletion of LAG-3 an 
earlier T cell development stage is obviated or altered such that a greater proportion of T 
cell precursors ultimately become graft-protective.  This theory is consistent with the 
evidence presented previously LAG-3 deletion functionally produces a higher proportion 
of memory T cells.  The principal difference in these two cases is the cytokine milieu.  In 
a pro-rejection microenvironment such as that of mouse heart or skin allotransplantation, 
then the net effect of germline LAG-3 deletion is to produce an anti-graft effect; whereas, 
in the tolerant microenvironment of kidney allotransplantation, then the corresponding 
net effect is a sustained immunoprotective response.   This theory is encapsulated by the 
overarching model presented below: 
 
 
One theory by which this may occur is that LAG-3 may depress differentiation of T cells 
by blocking co-stimulatory or activating MHC or glycoprotein signals.  Without LAG-3, 
cells are more likely to differentiate.  This model explains how an absence of LAG-3 in 
the in vitro experiments in this study can generate relatively higher expression of PD-1, 
IL-10, and FOXP3 on FACS analysis.  The relative proportions of certain cellular 
subtypes, primarily FOXP3 regulatory T cells and peripheral Tr1 cells, are greatly 
Fig. 16: Suggested Model of LAG-3 Control of T Cell Differentiation 
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enhanced in the absence of LAG-3 if LAG-3 exerts control through an undescribed 
mechanism over the differentiation of CD4+ precursors. 
 
Gal-3 and LAG-3 interract to affect cellular phenotype and properties 
 An interesting result that further contextualizes what has been previously 
published is that the glycoprotein Gal-3 functions as a ligand for LAG-3.  Although the 
binding of these two molecules was not directly tested in this study, we found evidence 
from co-culture FACS analysis that the level of Gal-3-dependent IL-10 and Foxp3 
expression is affected by the presence or absence of LAG-3.  Relative to LAG-3+/+ cell 
cultures, knockout cell cultures saw the relative expressions of IL-10 and Foxp3 increase 
from 3.49% and 5.04%, respectively, to 7.94% and 10.40%.  The highest expression 
(10.40%) occurred when LAG-3 was absent and Gal-3 was present, suggesting that LAG-
3 may be inhibiting receptor expression induced by Gal-3 and that the absence of LAG-3 
accelerates differentiation, as discussed earlier.  Interestingly, LAG-3 showed an even 
stronger effect in the case of PD-1 expression: Gal-3-dependent induction of PD-1 on 
CD4 cells only occurred in the absence of LAG-3.   While it has been previously reported 
that Gal-3 interacts with LAG-3 to suppress lymphocytes (27, 28), it also appears based 
on this work that LAG-3 can block the downstream effects of Gal-3 in this cytokine 
environment. 
  
Distinguishing the isoform and cellular types responsible for LAG-3’s effects 
The adoptive transfer experiments further demonstrate that the effects of surface-
bound LAG-3 appear to eclipse those of soluble LAG-3 for transplant outcomes.  
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Furthermore, even the cell type on which LAG-3 is expressed appears to influence the 
both skin graft rejection speed and memory response.  Mice with LAG-3-competent T 
cells from adoptive transfer injections experienced prolonged graft survival compared 
with LAG-3-/- graft recipients that did not receive injections.  However, it was LAG-3-
competent dendritic cells, rather than T cells, that were responsible for reduced anti-
donor response more than one month after skin engraftment. 
An area that has not yet been fully explored in the literature is the role of tolerant 
dendritic cell subsets in producing graft-protective microenvironments.  As master 
controllers and activators of cell classes, including T cells (49), dendritic cells are prime 
candidates for the cell type that would exert a very powerful effect on differentiation of 
CD4+ T cell precursors using LAG-3.  One subtype of dendritic cells that are DNGR-1+ 
has been shown to be important for cross-priming of naïve CD8+ T cells and the optimal 
production of tissue resident memory cells (50).  It is possible that another subset of 
dendritic cells analogously controls differentiation of naïve CD4+ T cells in a LAG-3 
dependent process that modulates transplantation outcomes.  In fact, LAG-3 has also 
been shown to be important for the development and homeostasis of dendritic cells and 
macrophages (8, 51), and LAG-3 is used by dendritic cells to influence the phenotypes 
and properties of other cells (5).  Interestingly, Gal-3, shown in this and prior studies to 
interact with LAG-3, has also been reported to modulate the function and expansion of 
dendritic cells and the CD8 T cells they activate (28, 52). 
While prior studies have demonstrated that LAG-3 is important for 
downregulating T cell activation and cellular proliferation (1-5), our results suggest that 
LAG-3 may also play an additional role in T cell biology by governing the differentiation 
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of naïve CD4+ T cells, both in rejection transplant models and tolerogenic transplant 
models.  Additionally, LAG-3’s role as a modulator of transplantation must also include 
its effect via dendritic cells, whose biological pathways with respect to effects 
downstream of LAG-3 require further exploration.  Past studies have shown that LAG-3 
is critical for dendritic cell activation and migration in some cases, but it is interesting 
that LAG-3 in this study depressed the anti-donor response, which would be consistent 
with either inhibition of dendritic cell activity or activation of an inhibitory dendritic cell 
subset.   
Overall, the primary contribution of this research to the area of transplantation 
and the broader field of immunology is the suggestion that LAG-3 may have a role in 
promoting T cell differentiation in a way that is separate from its roles in promoting the 
activation and proliferation of T cells.   This theory should be further substantiated and 
explored in related immunological research areas, such as tumor biology and infectious 
diseases.  An additional contribution of this research to the field is the finding that 
targeting LAG-3 alone is likely to be insufficient in adequately mediating either tolerance 
or rejection, because of its competing properties.  Rather, LAG-3 should be explored as a 
complementary therapy that eases the burden of broad immunosuppressives or other 
drugs that are aggressively antagonistic to the patient’s systemic health.   
 
Study Limitations & Future Directions 
 While the six conclusions generated by this study have produced novel results that 
can further illuminate our collective understanding of LAG-3 and its role in 
transplantation, there are aspects of the study results that need to be explored further.  
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First, the histologic results demonstrating vasculopathy should be stained to quantify the 
extent to which that antibody- or complement-mediated rejection are contributing to graft 
failure, as this may suggest alternative molecular mechanisms corresponding to LAG-3 
deletion.  Second, the role of Tr1 cells should be more definitively explored in more 
precise culturing experiments.  Due to time and resource constraints, we were not able to 
definitively identify the cultured T cells as Tr1 cells, due to a lack of CD49b expression.  
Because CD49b is a widespread cellular integrin alpha subunit, one would expect that it 
would not be broadly expressed on T cells cultured in vitro because they lack the 
appropriate microenvironment stimuli necessary for promoting expression of migration 
ligands and receptors.  It does appear that the expression of other functional Tr1 markers, 
LAG-3 (present) and Foxp3+ (absent), was consistent in the cell populations identified in 
our study as with those published in the literature (9).  Third, the interaction of Gal-3 and 
LAG-3 should be further explored to determine whether one molecule directly affects the 
induction of the other, possibly by using FACS sorting analysis.  Fourth, the adoptive 
transfer experiments used isolated dendritic cells, which were the basis for our study 
conclusions that dendritic cells are responsible for LAG-3-mediated memory control, but 
the isolation kits used do not reliably distinguish between dendritic cells and other 
antigen-presenting cells such as B cells.  Experiments should be conducted to tease apart 
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